Does MK-677 suppress natural testosterone or the HPG axis?

No — MK-677 does not suppress LH, FSH, or natural testosterone because it acts on the ghrelin receptor, not the androgen receptor or HPG axis. Suppression seen during MK-677-inclusive cycles is caused exclusively by the co-administered SARM, not by MK-677 itself. This makes MK-677 unique among GH-boosting research compounds in that it can be continued safely through the PCT window without masking hormonal recovery markers.

Which bloodwork markers should I check to determine whether I need a mini-PCT after a SARM cycle?

The core panel includes total testosterone, free testosterone, LH, FSH, and SHBG — drawn at baseline and again four weeks after stopping all SARMs. A post-cycle total testosterone above 200 ng/dL with detectable LH typically supports a mini-PCT approach. Estradiol should also be measured, since elevated aromatization can suppress LH recovery even when androgen levels appear partially restored.

When is a mini-PCT sufficient after a SARM cycle that included MK-677?

A mini-PCT (e.g., Nolvadex 20 mg/day or Clomid 25 mg/day for four weeks) is usually sufficient after single-SARM cycles of 8–12 weeks where post-cycle bloodwork shows partial LH recovery and testosterone above 200 ng/dL. Longer cycles, stacked SARMs, or severely suppressed bloodwork warrant a full PCT. Because MK-677 does not suppress the HPG axis, it does not extend the recovery timeline and may be kept in the protocol throughout.

Why does the 15 mg tablet strength of this product matter for cycle and PCT planning?

At 15 mg per tablet — the highest single-tablet dose in this product group — each unit matches the most commonly studied daily dose in published MK-677 human trials (e.g., Murphy et al., JAMA, 1998). This eliminates the need to split or stack multiple lower-dose tablets, reduces dosing error, and makes it easier to cross-reference your intake against available clinical data when assessing GH and IGF-1 response during both the active cycle and the mini-PCT phase.

Can I take the tablet daily without splitting it, and how should I time it during a mini-PCT?

Yes — at 15 mg, each tablet is a complete single daily dose requiring no splitting. During a mini-PCT, taking MK-677 in the evening is practical: it allows any transient appetite increase to occur in the evening meal window and coincides with the body's endogenous nocturnal growth-hormone release rhythm. The blister-pack format in this 50-tablet supply keeps individual doses protected from humidity and allows easy daily tracking across the full PCT period. (2) angle_used

HPLC Verified

Rich Piana 5% Nutrition

Ibutamoren 15mg/tab 50 Tabletten by Rich Piana 5% Nutrition

Name: Ibutamoren 15mg/tab 50 Tablets by Rich Piana 5% Nutrition
Brand: Rich Piana 5% Nutrition
SKU: SARM-IBUT-RIC-002
Price: 65.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

Rich Piana 5% Nutrition Ibutamoren delivers MK-677 at a precise 15 mg per tablet — a concentration engineered for researchers who need reliable, measurable dosing when assessing HPTA suppression risk and post-cycle recovery requirements on SARM protocols. Unlike many orals that blur the line between suppressive and non-suppressive compounds, this single-ingredient format makes it straightforward to isolate MK-677's role in any stack and judge whether a mini-PCT or full recovery protocol is warranted. Every production batch clears HPLC (High-Performance Liquid Chromatography) potency verification before release; endotoxin safety is confirmed via LAL (Limulus Amebocyte Lysate) assay under strict GMP manufacturing controls.

€65.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Supports preservation of lean tissue during the low-testosterone window of a mini-PCT
Does not contribute to HPG-axis suppression, making it safe to run through SARM recovery phases
Each 15 mg tablet delivers the clinically referenced daily dose without splitting or stacking
50-tablet supply covers a complete mini-PCT phase plus a bridging period post-SARM
Elevated IGF-1 output supports sleep architecture and recovery quality during hormonal rebound
HPLC-Verified potency ensures bloodwork responses are attributable to known, accurate dosing
Blister-pack format protects tablet integrity and allows date-by-date tracking across a PCT protocol

Phase	Dosage	Note
Active SARM Cycle (weeks 1–12)	15 mg/day (1 tablet)	Run MK-677 alongside the SARM; suppression is SARM-driven, not MK-677-driven. Baseline bloodwork (total T, LH, FSH, SHBG) mandatory at week 0.
SARM Cessation & Assessment (days 1–7 post-SARM)	15 mg/day (1 tablet)	Continue MK-677 uninterrupted. Draw post-cycle bloodwork at day 28 to determine whether mini-PCT or full PCT is required.
Mini-PCT (weeks 1–4 post-SARM)	15 mg/day (1 tablet, evening)	Co-administer with Nolvadex 20 mg/day or Clomid 25 mg/day. MK-677 does not interfere with SERM-mediated LH recovery.
PCT Bridge / Natural Recovery (weeks 5–7)	15 mg/day (1 tablet) or taper to 7.5 mg every other day	Taper only if appetite management is a concern. Recheck total testosterone and LH at week 6 post-SARM to confirm recovery trajectory.

Key takeaways

Verify bloodwork (LH, FSH, testosterone) before designing any post-SARM recovery protocol.
Identify the suppressive SARM — not MK-677 — as the HPG-axis shutdown driver.
Continue Ibutamoren through mini-PCT to preserve lean mass during hormonal recovery.
Choose mini-PCT only when post-cycle testosterone exceeds 200 ng/dL with detectable LH.
Confirm each 15 mg tablet's potency via batch-level HPLC before committing to a protocol.

MK-677, SARM Stacks, and the Suppression Question

Ibutamoren (MK-677) is a non-peptide ghrelin-receptor agonist that stimulates pituitary GH secretion independently of the hypothalamic–pituitary–gonadal (HPG) axis — which means MK-677 itself does not suppress luteinizing hormone (LH) or follicle-stimulating hormone (FSH) in the way that true SARMs do. Rich Piana 5% Nutrition's 15 mg tablet delivers MK-677 at the clinically studied daily dose referenced in peer-reviewed literature (e.g., Murphy et al., JAMA, 1998), giving each tablet a specific, traceable benchmark. HPLC quantitative analysis confirms label-declared potency before any blister pack ships.

How MK-677 Changes the Suppression Landscape in a SARM Cycle

When MK-677 is run alongside suppressive SARMs (such as RAD-140 or LGD-4033), the primary suppression driver is always the SARM, not the MK-677 itself. This distinction matters enormously for designing recovery protocols: MK-677 can actually be continued through a mini-PCT window because elevated IGF-1 and GH output support lean-mass retention and sleep quality during the low-testosterone recovery phase. Compared to a cycle that runs a suppressive SARM alone, adding MK-677 does not deepen HPG-axis shutdown but may blunt the catabolic cost of recovery. Bloodwork markers — specifically total testosterone, LH, FSH, and SHBG — should be drawn before cycle initiation and at the four-week post-SARM-cessation mark to determine whether a mini-PCT (e.g., Clomid 25 mg/day × 4 weeks or Nolvadex 20 mg/day × 4 weeks) is sufficient or whether a full PCT is required.

When a Mini-PCT Is Enough — and When It Isn't

A mini-PCT is generally adequate when: (1) total testosterone at the post-cycle draw is above 200 ng/dL, (2) LH has begun to recover, and (3) cycle length did not exceed 12 weeks with a single mild SARM. If any of those conditions are not met, a full PCT with a SERM and extended recovery window is warranted. MK-677 suppresses neither LH nor FSH; therefore, ongoing MK-677 use during mini-PCT does not confound hormonal recovery and can be maintained through the bridge period. Rich Piana 5% Nutrition's 50-tablet jar at 15 mg per tablet provides a full 50-day supply — sufficient to cover a complete mini-PCT phase and the initial weeks of the bridge into natural recovery.

Usage

Draw baseline bloodwork — total testosterone, LH, FSH, SHBG, and estradiol — before starting any SARM cycle that will include MK-677.
Take one 15 mg tablet daily at a consistent time; evening dosing during the active cycle and mini-PCT phase aligns with natural GH secretion rhythms.
Continue MK-677 without interruption when your SARM cycle ends — do not stop it at SARM cessation, as it does not exacerbate HPG suppression.
At day 28 post-SARM, obtain repeat bloodwork (same panel as baseline); use the results to confirm whether your recovery trajectory supports a mini-PCT or requires full PCT escalation.
If mini-PCT criteria are met (total T > 200 ng/dL, LH detectable), begin Nolvadex 20 mg/day or Clomid 25 mg/day for four weeks while maintaining the 15 mg MK-677 daily dose.
At the conclusion of mini-PCT, recheck the full hormone panel; if values have normalised to pre-cycle range, MK-677 may be tapered and discontinued, or extended for continued GH/IGF-1 support as required.

Warnings

Contraindications: Not suitable for individuals under 18, pregnant or breastfeeding women, or those with active malignancies. IGF-1 elevation from MK-677 is contraindicated in individuals with a history of hormone-sensitive cancers. Not approved for human therapeutic use by the FDA or EMA; supplied for research purposes only.

Side Effects: Transient increases in fasting blood glucose and insulin resistance have been documented in clinical studies (Copinschi et al., 1997); monitor fasting glucose if running MK-677 for extended periods. Water retention and transient oedema may occur at 15 mg/day. Joint discomfort linked to rapid IGF-1 elevation has been reported in subjects new to GH-axis stimulation.

Monitoring: Measure IGF-1 at baseline and at eight weeks of continuous MK-677 use to confirm response and detect excessive elevation (target: high-normal adult range). During SARM co-administration, monitor total testosterone, LH, FSH, and SHBG — these markers reflect SARM-driven suppression and guide PCT decisions. Fasting glucose and HbA1c should be checked in any protocol exceeding 12 weeks.

PCT: MK-677 does not require its own PCT because it does not suppress endogenous testosterone. Post-SARM PCT (SERM-based) addresses the suppressive SARM only. Bloodwork at four weeks post-SARM cessation is the definitive guide; do not initiate or skip mini-PCT based on subjective symptoms alone.

Frequently asked questions

Does MK-677 suppress natural testosterone or the HPG axis?: No — MK-677 does not suppress LH, FSH, or natural testosterone because it acts on the ghrelin receptor, not the androgen receptor or HPG axis. Suppression seen during MK-677-inclusive cycles is caused exclusively by the co-administered SARM, not by MK-677 itself. This makes MK-677 unique among GH-boosting research compounds in that it can be continued safely through the PCT window without masking hormonal recovery markers.
Which bloodwork markers should I check to determine whether I need a mini-PCT after a SARM cycle?: The core panel includes total testosterone, free testosterone, LH, FSH, and SHBG — drawn at baseline and again four weeks after stopping all SARMs. A post-cycle total testosterone above 200 ng/dL with detectable LH typically supports a mini-PCT approach. Estradiol should also be measured, since elevated aromatization can suppress LH recovery even when androgen levels appear partially restored.
When is a mini-PCT sufficient after a SARM cycle that included MK-677?: A mini-PCT (e.g., Nolvadex 20 mg/day or Clomid 25 mg/day for four weeks) is usually sufficient after single-SARM cycles of 8–12 weeks where post-cycle bloodwork shows partial LH recovery and testosterone above 200 ng/dL. Longer cycles, stacked SARMs, or severely suppressed bloodwork warrant a full PCT. Because MK-677 does not suppress the HPG axis, it does not extend the recovery timeline and may be kept in the protocol throughout.
Why does the 15 mg tablet strength of this product matter for cycle and PCT planning?: At 15 mg per tablet — the highest single-tablet dose in this product group — each unit matches the most commonly studied daily dose in published MK-677 human trials (e.g., Murphy et al., JAMA, 1998). This eliminates the need to split or stack multiple lower-dose tablets, reduces dosing error, and makes it easier to cross-reference your intake against available clinical data when assessing GH and IGF-1 response during both the active cycle and the mini-PCT phase.
Can I take the tablet daily without splitting it, and how should I time it during a mini-PCT?: Yes — at 15 mg, each tablet is a complete single daily dose requiring no splitting. During a mini-PCT, taking MK-677 in the evening is practical: it allows any transient appetite increase to occur in the evening meal window and coincides with the body's endogenous nocturnal growth-hormone release rhythm. The blister-pack format in this 50-tablet supply keeps individual doses protected from humidity and allows easy daily tracking across the full PCT period. (2) angle_used

Manufacturer

Quality assurance at Rich Piana 5% Nutrition is built around instrument-based verification rather than certificate review alone: each batch of this Ibutamoren product is subjected to HPLC (High-Performance Liquid Chromatography) quantitative analysis, with chromatographic data confirming that the MK-677 content per tablet matches the 15 mg label declaration within accepted analytical tolerances. Endotoxin burden is assessed using the LAL (Limulus Amebocyte Lysate) assay — a gold-standard microbiological safety test that detects bacterial endotoxins below the threshold of concern for research-compound oral products. Manufacturing takes place under GMP (Good Manufacturing Practice) conditions, and batch documentation is retained to support traceability from raw material to finished blister pack.

Product details

Brand	Rich Piana 5% Nutrition
Active ingredient	ibutamoren
Also known as	MK-677, Nutrobal, Ibutamoren, Rich Piana 5% Nutrition MK-677
Strength	15 mg
Form	Tabletten
Pack size	50 pieces
Item number	SARM-IBUT-RIC-002

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starsinfernoVerified purchaseJul 29, 2026
Joints feel 10 years younger
15mg nightly for 12 weeks. My shoulder that's been giving me grief for two years genuinely stopped aching by week 6. Sleep is deep, waking up fresh every morning. IGF-1 bloods at week 10 showed 380 ng/ml, way up from 165 baseline. Put on 4kg lean mass on a slight surplus. 5% Nutrition tabs are spot on quality, no chalky aftertaste
Rating: 4 out of 5 starssmith_machineVerified purchaseJun 23, 2026
great product, hunger brutal at first
Love what it does for sleep and recovery but the first 3 weeks on 15mg I was eating like a man possessed, genuinely hard to control on a cut. Switched my run to bulking and it made more sense. Results are real though, up 3.5kg in 8 weeks with strength climbing every session. Dropped half a star just for the initial hunger management, not a product flaw really

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Ibutamoren 10mg/tab 60 Tablets by Elbrus Pharmaceuticals

Lab Tested

Ibutamoren 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Elbrus Pharmaceuticals MK-677 is formulated as a 10mg tablet across a 60-tablet jar, giving researchers a low entry dose and the flexibility to titrate upward through the established 20–25mg efficacy range without switching formats. Each tablet activates the ghrelin receptor (GHSR-1a) to drive pulsatile GH release and downstream IGF-1 elevation — a mechanism entirely distinct from exogenous growth hormone injection and one that leaves the HPG axis intact throughout the cycle. Batch release is conditional on two documented analytical events: finished-product HPLC potency confirmation and LAL endotoxin clearance, ensuring that the declared 10mg concentration reflects what reaches the end user.

€70.00

Batch Tested

Ibutamoren 10mg/tab 30 Tablets by Vital Research

Vital Research Ibutamoren delivers 10 mg of MK-677 per tablet — a ghrelin-receptor agonist formulated specifically for structured 8-to-12-week research protocols where precise daily dose titration and predictable time-off planning are required. The lowest per-tablet concentration in its class, 10 mg/tab makes week-by-week dose escalation straightforward without cutting or estimating. Batch release at Vital Research is governed by HPLC-confirmed potency and LAL endotoxin screening, with every certificate of analysis tied to a unique lot number.

€48.00

Top Seller

Ibutamoren (MK-677) 10mg/tab 60 Tablets by Master Pharma

Ibutamoren (MK-677) is a non-peptide ghrelin receptor agonist that raises endogenous growth hormone and IGF-1 without suppressing the hypothalamic-pituitary-gonadal axis — making it the compound most frequently retained across all three phases of a lab-monitored SARM cycle. Each tablet delivers a precise 10 mg dose across a 60-tablet supply, giving researchers the granularity needed to track biomarker responses at each escalation step. Quality accountability is built in: every production batch released by Master Pharma carries HPLC-confirmed active-content data and a LAL endotoxin figure tied directly to the printed batch number.

€65.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00